Pinned Tweet
· Open Medicine Algorithm Spotlight ·
Sharing a practical LIVING @OpenMedicineHQ algorithm Multiple Myeloma at First Relapse: Treatment by Drug Sensitivity and Clinical Context (Last updated TODAY, November 6, 2026) by @ManniMD1
💭Key point: Finite-duration bispecific therapy, including approximately 6–12 months in selected contexts, is an individualized expert-practice or investigational stopping strategy—not a universal standard.
👉🏻LIVING ASCO GUIDELINE: ascopubs.org/doi/10.1200/JC…
👉🏻LIVING algorithm link: myopenmedicine.com/algorithms/mul…
#OpendMedicine
#Myeloma
#mmsm
@OpenMedKate
@scserendipity1
Sharing a practical LIVING @OpenMedicineHQ algorithm Multiple Myeloma at First Relapse: Treatment by Drug Sensitivity and Clinical Context (Last updated TODAY, November 6, 2026) by @ManniMD1
💭Key point: Finite-duration bispecific therapy, including approximately 6–12 months in selected contexts, is an individualized expert-practice or investigational stopping strategy—not a universal standard.
👉🏻LIVING ASCO GUIDELINE: ascopubs.org/doi/10.1200/JC…
👉🏻LIVING algorithm link: myopenmedicine.com/algorithms/mul…
#OpendMedicine
#Myeloma
#mmsm
@OpenMedKate
@scserendipity1
0
6
9
590
Open Medicine Insights retweeted
@OncBrothers @montypal @BijoyTelivala @RenoHemonc @DrYukselUrun @nataliagandur @AmandaNizamMD @SuyogCancer @MikeSerzanMD @bergsa83 @OncUpdates @drenriquegrande And we have a wonderful Livimg Algorithm from Monty to guide us, like having him next to us in clinic.
@OpenMedKate @OpenMedicineHQ @DrChoueiri @wandering_gu
myopenmedicine.com/algorithms/loc…
@OpenMedKate @OpenMedicineHQ @DrChoueiri @wandering_gu
myopenmedicine.com/algorithms/loc…
0
6
10
315
Video-demo: LIVING @OpenMedicineHQ Algorithm.
#myeloma
#OpenMedicine
#mmsm
@ManniMD1
Link: myopenmedicine.com/algorithms/mul…
#myeloma
#OpenMedicine
#mmsm
@ManniMD1
Link: myopenmedicine.com/algorithms/mul…
· Open Medicine Algorithm Spotlight ·
Sharing a practical LIVING @OpenMedicineHQ algorithm Multiple Myeloma at First Relapse: Treatment by Drug Sensitivity and Clinical Context (Last updated TODAY, November 6, 2026) by @ManniMD1
💭Key point: Finite-duration bispecific therapy, including approximately 6–12 months in selected contexts, is an individualized expert-practice or investigational stopping strategy—not a universal standard.
👉🏻LIVING ASCO GUIDELINE: ascopubs.org/doi/10.1200/JC…
👉🏻LIVING algorithm link: myopenmedicine.com/algorithms/mul…
#OpendMedicine
#Myeloma
#mmsm
@OpenMedKate
@scserendipity1
0
4
7
336
Open Medicine Insights retweeted
Metastatic Non-Small Cell Lung Cancer (NSCLC) Biomarker-Guided Treatment from @GlopesMd @Jani_Chinmay: myopenmedicine.com/algorithms/met…
1
5
5
298
Open Medicine Insights retweeted
Hi friends, it's #ProstateCancer Friday! Here are Top Posts of the Week 🧵
1/ @scocmem on talazoparib + enza vs placebo + enza in mCRPC (TALAPRO-2):
x.com/scocmem/status…
1/ @scocmem on talazoparib + enza vs placebo + enza in mCRPC (TALAPRO-2):
x.com/scocmem/status…
New biomarker analysis from TALAPRO-2 @TheLancetOncol
Baseline ctDNA and early dynamics correlated with rPFS, adding prognostic value beyond PSA in some patients
Integrating ctDNA, circulating tumour cells and PSA warrants further exploration @OncoAlert
sciencedirect.com/science/articl…
2
7
10
604
Open Medicine Insights retweeted
A major update from ASTCT! New consensus grading criteria refine CRS and ICANS assessments and address emerging toxicities following immune effector cell therapy, supporting standardized toxicity evaluation across clinical trials and practice. ow.ly/Wsig5103RX0
3
43
96
5,050
Open Medicine Insights retweeted
Beyond excited! My third book, "AI and Cancer Care: When Machines Meet Modern Medicine," launches 12/1/2026
What's real, what's hype, and how is AI transforming cancer care?
A nontechnical look at research and expert insight
📷 Preorder: amazon.com/dp/1421455625
Hope you enjoy it
What's real, what's hype, and how is AI transforming cancer care?
A nontechnical look at research and expert insight
📷 Preorder: amazon.com/dp/1421455625
Hope you enjoy it
9
9
60
2,725
• Open Medicine Algorithm Spotlight •
Sharing a practical @OpenMedicineHQ algorithm “Primary Plasma Cell Leukemia (PCL)” by @HadidiSamer (Last updated October 16, 2026).
Key points:
- Primary PCL: Confirm diagnosis and assess for presence of t(11;14)
- VD-PACE (in most patients):
* Consider one cycle of VD-PACE at time of diagnosis (if possible) for cyto-reduction and immediate disease control.
* Given for 2 cycles prior to tandem ASCT or as 1 cycle followed by 4-6 cycles of 4-drugs prior to tandem ASCT.
To view the complete LIVING algorithm, go to the link: myopenmedicine.com/algorithms/pri…
#OpendMedicine
#Myeloma
#mmsm
@OpenMedKate
@scserendipity1
0
6
6
401
Open Medicine Insights retweeted
Hi friends, it's #AcuteMyeloidLeukemia Thursday! Here are Top Posts of the Week 🧵
1/ @doctorpemm @TapKadia @HannahGoulart on cladribine-based approach in R/R #AML:
x.com/doctorpemm/sta…
1/ @doctorpemm @TapKadia @HannahGoulart on cladribine-based approach in R/R #AML:
x.com/doctorpemm/sta…
👉👉👉Highlighting the #Cladribine - based approach for treatment of Patients with AML championed by Prof .@TapKadia & our team - great job Dr .@HannahGoulart leading this paper on #CLIA program for patients with R/R AML | @UTMDAnderson #endcancer
acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn…
1
8
18
1,083
Open Medicine Algorithm Spotlight ·
Sharing a practical @OpenMedicineHQ algorithm “Toxicity management for esophageal stricture” by Nina Sanford, MD @NiuSanford
(Last updated October 16, 2026).
Key points:
- Before therapeutic endoscopy, confirm benign disease with nd biopsy of a new stricture
- Use contrast esophagram or CT when the stricture is long, angulated, complex, completely obstructing, or associated with a suspected fistula
- Radiation strictures are delayed toxicities and may become clinically apparent months or years after treatment. Timing is variable, so the node is directionally accurate rather than a strict diagnostic interval.
- Dilation: usually requires multiple sessions (~3), done gradually to reduce risk of perforation —> Can stent if refractory.
To view the complete LIVING algorithm, go to the link: myopenmedicine.com/algorithms/tox…
Video-demo:
#OpendMedicine
@OpenMedKate
@OpenMedicineHQ
@scserendipity1
Sharing a practical @OpenMedicineHQ algorithm “Toxicity management for esophageal stricture” by Nina Sanford, MD @NiuSanford
(Last updated October 16, 2026).
Key points:
- Before therapeutic endoscopy, confirm benign disease with nd biopsy of a new stricture
- Use contrast esophagram or CT when the stricture is long, angulated, complex, completely obstructing, or associated with a suspected fistula
- Radiation strictures are delayed toxicities and may become clinically apparent months or years after treatment. Timing is variable, so the node is directionally accurate rather than a strict diagnostic interval.
- Dilation: usually requires multiple sessions (~3), done gradually to reduce risk of perforation —> Can stent if refractory.
To view the complete LIVING algorithm, go to the link: myopenmedicine.com/algorithms/tox…
Video-demo:
#OpendMedicine
@OpenMedKate
@OpenMedicineHQ
@scserendipity1
0
5
7
291
Open Medicine Insights retweeted
What has changed in follicular lymphoma management in recent years?
New advances in diagnosis and treatment continue to expand the options available to patients with follicular lymphoma. The EHA Clinical Practice Guidelines for Newly Diagnosed and Relapsed Follicular Lymphoma st evidence and expert recommendations to support clinical decision-making.
The guideline addresses both newly diagnosed and relapsed disease, with practical recommendations for diagnosis, treatment, and follow-up, while emphasizing individualized care and shared decision-making.
Swipe through the carousel for key highlights and access the full guideline here: eha.fyi/FL-guidelines
New advances in diagnosis and treatment continue to expand the options available to patients with follicular lymphoma. The EHA Clinical Practice Guidelines for Newly Diagnosed and Relapsed Follicular Lymphoma st evidence and expert recommendations to support clinical decision-making.
The guideline addresses both newly diagnosed and relapsed disease, with practical recommendations for diagnosis, treatment, and follow-up, while emphasizing individualized care and shared decision-making.
Swipe through the carousel for key highlights and access the full guideline here: eha.fyi/FL-guidelines
0
4
12
893
Open Medicine Insights retweeted
The November issue is out now! Highlights include feature on alternative care models and solutions to address hematology workforce shortages, expert insight on a challenging case of relapsed extranodal NK/T-cell lymphoma, and more. See the full lineup 👉 ow.ly/uHH55103IRF
0
3
6
781
• Open Medicine Algorithm Spotlight •
Sharing a practical @OpenMedicineHQ algorithm “Primary Plasma Cell Leukemia (PCL)” by @HadidiSamer (Last updated October 16, 2026).
Key points:
- Primary PCL: Confirm diagnosis and assess for presence of t(11;14)
- VD-PACE (in most patients):
* Consider one cycle of VD-PACE at time of diagnosis (if possible) for cyto-reduction and immediate disease control.
* Given for 2 cycles prior to tandem ASCT or as 1 cycle followed by 4-6 cycles of 4-drugs prior to tandem ASCT.
To view the complete LIVING algorithm, go to the link: myopenmedicine.com/algorithms/pri…
#OpendMedicine
#Myeloma
#mmsm
@OpenMedKate
@scserendipity1
Sharing a practical @OpenMedicineHQ algorithm “Primary Plasma Cell Leukemia (PCL)” by @HadidiSamer (Last updated October 16, 2026).
Key points:
- Primary PCL: Confirm diagnosis and assess for presence of t(11;14)
- VD-PACE (in most patients):
* Consider one cycle of VD-PACE at time of diagnosis (if possible) for cyto-reduction and immediate disease control.
* Given for 2 cycles prior to tandem ASCT or as 1 cycle followed by 4-6 cycles of 4-drugs prior to tandem ASCT.
To view the complete LIVING algorithm, go to the link: myopenmedicine.com/algorithms/pri…
#OpendMedicine
#Myeloma
#mmsm
@OpenMedKate
@scserendipity1
0
8
8
886
Open Medicine Insights retweeted
Penile Cancer Diagnostic Workup from @Dr_Andrology: myopenmedicine.com/algorithms/pen…
1
4
3
186
Open Medicine Insights retweeted
Hi friends, it's #LungCancer Wednesday! Here are Top Posts of the Week 🧵
1/ @StephenVLiu @peters_solange @JoeChangMD on TERESA at ESMO26:
x.com/StephenVLiu/st…
1/ @StephenVLiu @peters_solange @JoeChangMD on TERESA at ESMO26:
x.com/StephenVLiu/st…
#ESMO26 Proud to share results from the TERESA study with Drs. @peters_solange @JoeChangMD et al: Real world treatment patterns and outcomes in pts with stage I-II NSCLC who did not undergo resection. In this Flatiron real world analysis, 40% of pts with stage I-II NSCLC did not of those pts received SBRT. Study of systemic therapy in this pt population represents an important opportunity to improve outcomes and is feasible, based on the size of the real world population.
1
4
9
542
Open Medicine Insights retweeted
Hi friends, it's #BreastCancer Tuesday! Here are Top Posts of the Week 🧵
1/ @PTarantinoMD on pathological and clinical landscape of HER2-low breast cancer:
x.com/PTarantinoMD/s…
1/ @PTarantinoMD on pathological and clinical landscape of HER2-low breast cancer:
x.com/PTarantinoMD/s…
6 years ago, I had the chance to publish a paper that would end up changing my academic life
It was a review article exploring the surprising activity of certain ADCs in “HER2-low” breast cancer, a newly emerging entity whose relevance was still uncertain.
We tried to connect 2-low was a subtype vs just a target, wondering whether this concept could one day translate into meaningful benefits for patients.
6 years later, that article has reached 1,000 citations. My career has gifted me more than I could ever have imagined. More importantly, what was once an intriguing scientific observation has become a clinical reality: countless patients with HER2-low breast cancer now live longer thanks to T-DXd.
A reminder of how far science can take us in just a few years.
Grateful to everyone who has been part of this journey!
ascopubs.org/doi/10.1200/JC…
1
6
24
1,857
· Open Medicine Algorithm Spotlight ·
Sharing a practical @OpenMedicineHQ algorithm “Relapsed or Resistant Chronic-Phase Chronic Myeloid Leukemia Treatment” (Last updated October 27, 2026) by @TalhaBadarMD
Key points:
- Assess the BCR::ABL1 molecular response trajectory and is an inadequate response or loss of a previously achieved response.
- Do not base a treatment switch on a single unexpected PCR result alone. Review the molecular trajectory together with adherence, dose interruptions or reductions, drug interactions, comorbidities, and potential laboratory variability.
- Clinically important response values include >10% at 3 months when confirmed, >10% at 6 months, >1% at 12 months, or loss of a prior response
myopenmedicine.com/algorithms/rel…
Video-demo:
#OpenMedicine
@OpenMedKate
@scserendipity1
Sharing a practical @OpenMedicineHQ algorithm “Relapsed or Resistant Chronic-Phase Chronic Myeloid Leukemia Treatment” (Last updated October 27, 2026) by @TalhaBadarMD
Key points:
- Assess the BCR::ABL1 molecular response trajectory and is an inadequate response or loss of a previously achieved response.
- Do not base a treatment switch on a single unexpected PCR result alone. Review the molecular trajectory together with adherence, dose interruptions or reductions, drug interactions, comorbidities, and potential laboratory variability.
- Clinically important response values include >10% at 3 months when confirmed, >10% at 6 months, >1% at 12 months, or loss of a prior response
myopenmedicine.com/algorithms/rel…
Video-demo:
#OpenMedicine
@OpenMedKate
@scserendipity1
0
8
6
408
NEWS 🗞️• Updates in acute graft-versus-host disease: From novel pathogenic mechanisms to emerging therapeutic targets
@BrJHaem
onlinelibrary.wiley.com/doi/10.1111/bj…
@BrJHaem
onlinelibrary.wiley.com/doi/10.1111/bj…
0
3
11
753